Text Size
1353 studies found for:    melanoma

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
melanoma
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Characterization of the Melanoma-Specific Immune Response
Condition: Melanoma
Intervention:
2 Unknown † Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
Conditions: Advanced Melanoma;   Untreated Patients
Interventions: Drug: dacarbazine plus Endostar (Experimental group);   Drug: dacarbazine plus placebo (control group)
3 Completed
Has Results 		MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
4 Active, not recruiting
Has Results 		Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: melanoma helper peptide vaccine;   Biological: multi-epitope melanoma peptide vaccine;   Biological: sargramostim;   Biological: tetanus peptide melanoma vaccine
5 Recruiting Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
Condition: Melanoma
Interventions: Biological: melanoma GVAX;   Drug: Cyclophosphamide
6 Completed Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma
Condition: Melanoma
Interventions: Drug: low-dose IL-2;   Biological: melanoma vaccine
7 Active, not recruiting Melanoma Risk-Reduction Among Patients and Family Members
Condition: Melanoma
Interventions: Behavioral: Questionnaire;   Behavioral: Interview
8 Active, not recruiting Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma
Condition: Melanoma
Intervention: Biological: 4-peptide and 12-peptide melanoma vaccines
9 Terminated
Has Results 		Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental
Interventions: Drug: DMF5 Melanoma Reactive TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
10 Not yet recruiting Melanoma Margins Excision Trial
Condition: Melanoma
Intervention: Procedure: Surgical Excision Margin
11 Active, not recruiting Vaccination Plus Ontak in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: 4-peptide melanoma vaccine;   Drug: 4-peptide melanoma vaccine plus Ontak;   Drug: ontak
12 Unknown † Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: melanoma helper peptide vaccine;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Drug: cyclophosphamide
13 Recruiting Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
Conditions: Hereditary Multiple Melanoma;   Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: molecular genetic technique;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
14 Completed Comparison of Video-Based Versus Written Patient Education on Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Other: Patient Educational Materials
15 Unknown † Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes
Condition: Melanoma (Skin)
Interventions: Biological: HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine;   Biological: HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine;   Biological: autologous melanoma lysate-pulsed autologous dendritic cell vaccine;   Biological: autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine;   Biological: dendritic cell-idiotype-keyhole limpet hemocyanin vaccine;   Other: flow cytometry;   Procedure: adjuvant therapy
16 Unknown † Vaccine Therapy in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: QS21;   Biological: incomplete Freund's adjuvant;   Biological: peptide 946 melanoma vaccine;   Biological: peptide 946-tetanus peptide conjugate melanoma vaccine;   Biological: tetanus peptide melanoma vaccine
17 Completed
Has Results 		Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Condition: Melanoma
Interventions: Drug: Glycoprotein 100 (GP100): 209-217 (210M);   Drug: Interleukin-2 (IL-2);   Drug: Montanide ISA 51;   Drug: Melanoma antigen recognized by T-cells (MART)-1: 27-35;   Drug: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1;   Drug: melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)
18 Recruiting Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
19 Recruiting Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
Condition: Melanoma
Intervention: Other: biological collection
20 Completed Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
Conditions: Stage IV Melanoma;   Recurrent Melanoma
Intervention: Biological: recombinant interferon beta
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years